The use of Bacillus Calmette-Guerin (BCG) expanded this year to just under half of all facilities nationwide, and this number holds steady across facilities of all sizes.

Just 4 years ago, CAR-T therapy was only available in 18% of hospitals in the US. It has now expanded to 26% of all facilities nationwide, and is available in a majority of the largest facilities.

This year saw a notable increase in the number of facilities that handle, compound, or administer viral vectors, such as gene therapy, from 13% to 19%. While just 19% of facilities nationwide are handling viral vectors, that number jumps to 38% of facilities with 400+ beds.